Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.

Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK.

Ther Adv Med Oncol. 2017 Apr;9(4):287-298. doi: 10.1177/1758834016687261. Epub 2017 Feb 14. Review.

2.

Systemic adjuvant therapies in renal cell carcinoma.

Buti S, Bersanelli M, Donini M, Ardizzoni A.

Oncol Rev. 2012 Oct 8;6(2):e18. doi: 10.4081/oncol.2012.e18. eCollection 2012 Oct 2. Review.

3.

Covalent crosslinking of tumor antigens stimulates an antitumor immune response.

Wang Y, Wang XY, Subjeck JR, Kim HL.

Vaccine. 2010 Sep 14;28(40):6613-20. doi: 10.1016/j.vaccine.2010.07.060. Epub 2010 Aug 2.

4.

A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.

Van Veldhuizen PJ, Hussey M, Lara PN Jr, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE.

Am J Clin Oncol. 2009 Oct;32(5):453-9.

5.
6.

Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.

Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA.

J Urol. 2008 Feb;179(2):730-6. Epub 2007 Dec 20.

7.

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA.

J Clin Oncol. 2003 Aug 15;21(16):3127-32.

8.

Immunotherapy for renal carcinoma: theoretical basis and current standard of care.

Vasey PA.

Br J Clin Pharmacol. 2000 Dec;50(6):521-9. Review. No abstract available.

Supplemental Content

Support Center